After Chardan Capital and Roth Capital gave Logicbio Therapeutics Inc (NASDAQ: LOGC) a Buy rating last month, the company received another Buy, this time from William Blair. Analyst Raju Prasad maintained a Buy rating on Logicbio Therapeutics Inc today. The company’s shares opened today at $14.11.
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 20.9% and a 59.1% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Allogene Therapeutics Inc.
Currently, the analyst consensus on Logicbio Therapeutics Inc is a Strong Buy with an average price target of $23, implying a 63.0% upside from current levels. In a report issued on May 1, Roth Capital also initiated coverage with a Buy rating on the stock with a $26 price target.
See today’s analyst top recommended stocks >>
Based on Logicbio Therapeutics Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $7.06 million. In comparison, last year the company had a GAAP net loss of $1.04 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LogicBio Therapeutics, Inc. is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene.
